Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle

Anti-cancer agent doxorubicin (DOX) has been demonstrated to worsen insulin signaling, engender muscle atrophy, trigger pro-inflammation, and induce a shift to anaerobic glycolytic metabolism in skeletal muscle. The myotoxicity of DOX in diabetic skeletal muscle remains largely unclear. This study e...

Full description

Bibliographic Details
Main Authors: Rashmi Supriya, Bjorn Tam, Xiao Pei, Christopher Lai, Lawrence Wing Chi Chan, Benjamin Yung, Parco M Siu
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-07-01
Series:Frontiers in Physiology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00323/full
id doaj-8f9b15933f464702a8ef423ab39c8a97
record_format Article
spelling doaj-8f9b15933f464702a8ef423ab39c8a972020-11-24T20:47:57ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2016-07-01710.3389/fphys.2016.00323210410Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscleRashmi Supriya0Bjorn Tam1Xiao Pei2Christopher Lai3Lawrence Wing Chi Chan4Benjamin Yung5Parco M Siu6The Hong Kong Polytechnic UniversityThe Hong Kong Polytechnic UniversityThe Hong Kong Polytechnic UniversityThe Hong Kong Polytechnic UniversityThe Hong Kong Polytechnic UniversityThe Hong Kong Polytechnic UniversityThe Hong Kong Polytechnic UniversityAnti-cancer agent doxorubicin (DOX) has been demonstrated to worsen insulin signaling, engender muscle atrophy, trigger pro-inflammation, and induce a shift to anaerobic glycolytic metabolism in skeletal muscle. The myotoxicity of DOX in diabetic skeletal muscle remains largely unclear. This study examined the effects of DOX on insulin signaling, muscle atrophy, pro-/anti-inflammatory microenvironment, and glycolysis metabolic regulation in skeletal muscle of db/db diabetic and db/+ non-diabetic mice. Non-diabetic db/+ mice and diabetic db/db mice were randomly assigned to the following groups: db/+CON, db/+DOX, db/dbCON, and db/dbDOX. Mice in db/+DOX and db/dbDOX groups were intraperitoneally injected with DOX at a dose of 15 mg per kg body weight whereas mice in db/+CON and db/dbCON groups were injected with the same volume of saline instead of DOX. Gastrocnemius was immediately harvested, weighed, washed with cold phosphate buffered saline, frozen in liquid nitrogen, and stored at -80 ºC for later analysis. The effects of DOX on diabetic muscle were neither seen in insulin signaling markers (Glut4, pIRS1Ser636/639, and pAktSer473) nor muscle atrophy markers (muscle mass, MuRF1 and MAFbx). However, DOX exposure resulted in enhancement of pro-inflammatory favoring microenvironment (as indicated by TNF-α, HIFα and pNFκBp65) accompanied by diminution of anti-inflammatory favoring microenvironment (as indicated by IL15, PGC1α and pAMPKβ1Ser108). Metabolism of diabetic muscle was shifted to anaerobic glycolysis after DOX exposure as demonstrated by our analyses of PDK4, LDH and pACCSer79. Our results demonstrated that there might be a link between inflammatory modulation and the dysregulation of aerobic glycolytic metabolism in DOX-injured diabetic skeletal muscle. These findings help to understand the pathogenesis of DOX-induced myotoxicity in diabetic muscle.http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00323/fullanti-inflammationtype 2 diabetes mellituscancer chemotherapymyotoxicityAnaerobic glycolysisPro-inflammation
collection DOAJ
language English
format Article
sources DOAJ
author Rashmi Supriya
Bjorn Tam
Xiao Pei
Christopher Lai
Lawrence Wing Chi Chan
Benjamin Yung
Parco M Siu
spellingShingle Rashmi Supriya
Bjorn Tam
Xiao Pei
Christopher Lai
Lawrence Wing Chi Chan
Benjamin Yung
Parco M Siu
Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle
Frontiers in Physiology
anti-inflammation
type 2 diabetes mellitus
cancer chemotherapy
myotoxicity
Anaerobic glycolysis
Pro-inflammation
author_facet Rashmi Supriya
Bjorn Tam
Xiao Pei
Christopher Lai
Lawrence Wing Chi Chan
Benjamin Yung
Parco M Siu
author_sort Rashmi Supriya
title Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle
title_short Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle
title_full Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle
title_fullStr Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle
title_full_unstemmed Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle
title_sort doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle
publisher Frontiers Media S.A.
series Frontiers in Physiology
issn 1664-042X
publishDate 2016-07-01
description Anti-cancer agent doxorubicin (DOX) has been demonstrated to worsen insulin signaling, engender muscle atrophy, trigger pro-inflammation, and induce a shift to anaerobic glycolytic metabolism in skeletal muscle. The myotoxicity of DOX in diabetic skeletal muscle remains largely unclear. This study examined the effects of DOX on insulin signaling, muscle atrophy, pro-/anti-inflammatory microenvironment, and glycolysis metabolic regulation in skeletal muscle of db/db diabetic and db/+ non-diabetic mice. Non-diabetic db/+ mice and diabetic db/db mice were randomly assigned to the following groups: db/+CON, db/+DOX, db/dbCON, and db/dbDOX. Mice in db/+DOX and db/dbDOX groups were intraperitoneally injected with DOX at a dose of 15 mg per kg body weight whereas mice in db/+CON and db/dbCON groups were injected with the same volume of saline instead of DOX. Gastrocnemius was immediately harvested, weighed, washed with cold phosphate buffered saline, frozen in liquid nitrogen, and stored at -80 ºC for later analysis. The effects of DOX on diabetic muscle were neither seen in insulin signaling markers (Glut4, pIRS1Ser636/639, and pAktSer473) nor muscle atrophy markers (muscle mass, MuRF1 and MAFbx). However, DOX exposure resulted in enhancement of pro-inflammatory favoring microenvironment (as indicated by TNF-α, HIFα and pNFκBp65) accompanied by diminution of anti-inflammatory favoring microenvironment (as indicated by IL15, PGC1α and pAMPKβ1Ser108). Metabolism of diabetic muscle was shifted to anaerobic glycolysis after DOX exposure as demonstrated by our analyses of PDK4, LDH and pACCSer79. Our results demonstrated that there might be a link between inflammatory modulation and the dysregulation of aerobic glycolytic metabolism in DOX-injured diabetic skeletal muscle. These findings help to understand the pathogenesis of DOX-induced myotoxicity in diabetic muscle.
topic anti-inflammation
type 2 diabetes mellitus
cancer chemotherapy
myotoxicity
Anaerobic glycolysis
Pro-inflammation
url http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00323/full
work_keys_str_mv AT rashmisupriya doxorubicininducesinflammatorymodulationandmetabolicdysregulationindiabeticskeletalmuscle
AT bjorntam doxorubicininducesinflammatorymodulationandmetabolicdysregulationindiabeticskeletalmuscle
AT xiaopei doxorubicininducesinflammatorymodulationandmetabolicdysregulationindiabeticskeletalmuscle
AT christopherlai doxorubicininducesinflammatorymodulationandmetabolicdysregulationindiabeticskeletalmuscle
AT lawrencewingchichan doxorubicininducesinflammatorymodulationandmetabolicdysregulationindiabeticskeletalmuscle
AT benjaminyung doxorubicininducesinflammatorymodulationandmetabolicdysregulationindiabeticskeletalmuscle
AT parcomsiu doxorubicininducesinflammatorymodulationandmetabolicdysregulationindiabeticskeletalmuscle
_version_ 1716809468376776704